Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

The objective was to undertake an early cost-effectiveness assessment of valoctocogene roxaparvovec (valrox; Roctavian) compared to factor (F)VIII prophylaxis or emicizumab (Hemlibra; Roche HQ, Bazel, Switzerland) in patients with severe Hemophilia A (HA) without FVIII-antibodies. We also aimed to i...

Full description

Bibliographic Details
Main Authors: Renske M.T. ten Ham, Sikon M. Walker, Marta O. Soares, Geert W.J. Frederix, Frank W.G. Leebeek, Kathelijn Fischer, Michiel Coppens, Stephen J. Palmer
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000679

Internet

http://journals.lww.com/10.1097/HS9.0000000000000679

Similar Items